Phase 1 Trial of Cyclosporine for Hospitalized Patients with COVID-19
View ORCID ProfileEmily A. Blumberg, View ORCID ProfilePablo Tebas, Ian Frank, Amy Marshall, Anne Chew, Elizabeth A. Veloso, Alison Carulli, Walter Rogal, Avery L. Gaymon, Aliza H. Schmidt, Tiffany Barnette, Renee Jurek, Hooman Noorchashm, Wei-Ting Hwang, Julia Han Noll, View ORCID ProfileJoseph A. Fraietta, View ORCID ProfileCarl H. June, Elizabeth O. Hexner
doi: https://doi.org/10.1101/2021.06.10.21258714
Emily A. Blumberg
1Department of Medicine, Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA
Pablo Tebas
1Department of Medicine, Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA
Ian Frank
1Department of Medicine, Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA
Amy Marshall
2Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA
Anne Chew
2Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA
Elizabeth A. Veloso
2Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA
Alison Carulli
3Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA USA
Walter Rogal
2Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA
Avery L. Gaymon
2Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA
Aliza H. Schmidt
2Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA
Tiffany Barnette
2Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA
Renee Jurek
2Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA
Hooman Noorchashm
4Yardley, PA USA
Wei-Ting Hwang
5Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA
Julia Han Noll
2Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA
6Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA
7Parker Institute for Cancer Immunotherapy, University of Pennsylvania, PA, USA
Joseph A. Fraietta
2Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA
6Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA
7Parker Institute for Cancer Immunotherapy, University of Pennsylvania, PA, USA
Carl H. June
1Department of Medicine, Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA
7Parker Institute for Cancer Immunotherapy, University of Pennsylvania, PA, USA
Elizabeth O. Hexner
1Department of Medicine, Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA
8Department of Medicine, Division of Hematology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA
Data Availability
Any data that support the findings of this study are available from the corresponding author upon reasonable request.
Posted June 15, 2021.
Phase 1 Trial of Cyclosporine for Hospitalized Patients with COVID-19
Emily A. Blumberg, Pablo Tebas, Ian Frank, Amy Marshall, Anne Chew, Elizabeth A. Veloso, Alison Carulli, Walter Rogal, Avery L. Gaymon, Aliza H. Schmidt, Tiffany Barnette, Renee Jurek, Hooman Noorchashm, Wei-Ting Hwang, Julia Han Noll, Joseph A. Fraietta, Carl H. June, Elizabeth O. Hexner
medRxiv 2021.06.10.21258714; doi: https://doi.org/10.1101/2021.06.10.21258714
Phase 1 Trial of Cyclosporine for Hospitalized Patients with COVID-19
Emily A. Blumberg, Pablo Tebas, Ian Frank, Amy Marshall, Anne Chew, Elizabeth A. Veloso, Alison Carulli, Walter Rogal, Avery L. Gaymon, Aliza H. Schmidt, Tiffany Barnette, Renee Jurek, Hooman Noorchashm, Wei-Ting Hwang, Julia Han Noll, Joseph A. Fraietta, Carl H. June, Elizabeth O. Hexner
medRxiv 2021.06.10.21258714; doi: https://doi.org/10.1101/2021.06.10.21258714
Subject Area
Subject Areas
- Addiction Medicine (313)
- Allergy and Immunology (616)
- Anesthesia (158)
- Cardiovascular Medicine (2253)
- Dermatology (199)
- Emergency Medicine (368)
- Epidemiology (11542)
- Forensic Medicine (10)
- Gastroenterology (676)
- Genetic and Genomic Medicine (3539)
- Geriatric Medicine (336)
- Health Economics (611)
- Health Informatics (2283)
- Health Policy (909)
- Hematology (333)
- HIV/AIDS (741)
- Medical Education (357)
- Medical Ethics (100)
- Nephrology (385)
- Neurology (3322)
- Nursing (189)
- Nutrition (504)
- Oncology (1747)
- Ophthalmology (521)
- Orthopedics (208)
- Otolaryngology (283)
- Pain Medicine (221)
- Palliative Medicine (66)
- Pathology (434)
- Pediatrics (997)
- Primary Care Research (398)
- Public and Global Health (5966)
- Radiology and Imaging (1213)
- Respiratory Medicine (806)
- Rheumatology (367)
- Sports Medicine (309)
- Surgery (383)
- Toxicology (50)
- Transplantation (169)
- Urology (142)